- Active Pharmaceutical Ingredients
- Varenicline tartrate
- Aprepitant, Fosapitant Intermediates
- Fosaprepitant Dimeglumine
- Vildagliptin
- Efinaconazole
- Luliconazole Intermediate
- Gadoterate Meglumine
- Succinyl Alcohol Intermediate
- Mirabillon Intermediate
- Atazanavir Intermediate
- Intermediate
- Varenicline tartrate
- Aprepitant 287930-73-8
- Aprepitant 127852-28-2
- Aprepitant 287930-75-0
- Aprepitant 200000-59-5
- Aprepitant 155742-64-6
- Aprepitant 252742-72-6
- Fosaprepitant Dimeglumine 990-91-0
- Fosaprepitant Dimeglumine 265121-01-5
- Vildagliptin 207557-35-5
- Vildagliptin 702-82-9
- Efinaconazole 144230-50-2
- Efinaconazole 133775-25-4
- Efinaconazole 127000-90-2
- Gadoterate Meglumine
- Mirabegron
- Luliconazole 98873-55-3
- Luliconazole 126534-31-4
- Atazanavir sulfate
- Bortezomib 179324-87-9
- Bortezomib 114457-94-2
- Bortezomib 205393-22-2
- Brinzolamide
- Rivaroxaban Intermediate 446292-08-6
- Rivaroxaban Intermediate 446292-07-5
- Cinacalcet Hydrochloride 1005450-55-4
- Cinacalcet Hydrochloride 585-50-2
- Eletriptan Intermediate
- Indacaterol intermediate 312753-53-0
- Indacaterol intermediate 173140-90-4
- Sitagliptin Intermediate
- Fosanavir Calcium Intermediate
Popular information
Vintagliptin intermediate
【目录号】AP8107
【CAS #】446292-08-6
【分子式】C22H19N3O6
【产品简介】 2-[[(5S)-2-氧代-3-[4-(3-氧代-4-吗啉基)苯基]-5-噁唑烷基]甲基]-1H-异吲哚-1,3(2H)-二酮，英文名为 2-[[(5S)-2-Oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-5-oxazolidinyl]-methyl]-1H-isoindole-1,3(2H)-dione，美国化学文摘登记号为cas 446292-08-6。
Vintagliptin intermediate
(2S)-1-(Chloroacetyl)-2-pyrrolidinecarbonitrile
CAS 207557-35-5
Alias Vinitaliptin Intermediate
Catalog number AP2705
CAS # 207557-35-5
Molecular formula C7H9ClN2O
Molecular weight 172.61
Structural formula
Product introduction
CAS 207557-35-5 (2S) -N-chloroacetyl-2-cyanotetrahydropyrrole, the English name is (2S) -1- (Chloroacetyl) -2-
pyrrolidinecarbonitrile, U.S. Chemical Abstracts Registry No. cas 207557-35-5.
(2S) -N-chloroacetyl-2-cyanotetrahydropyrrole (CAS 207557-35-5) is an intermediate of vidagliptin. Vidagliptin is a selective, competitive, and reversible DPP_4 inhibitor. By combining with DPP-4 to form a DPP-4 complex to inhibit the activity of the enzyme, while increasing the concentration of GLP-1 and promoting the production of insulin by islet B cells, it also lowers the concentration of glucagon, thereby reducing blood glucose, and has no effect on body weight. Significant impact. This product is an oral anti-diabetic drug.
VIWIT 沪ICP备12014533号-1
